Literature DB >> 3470135

The karyotype of blastic crisis.

G Alimena, M R De Cuia, D Diverio, R Gastaldi, M Nanni.   

Abstract

The nonrandomness of chromosome clonal evolution in blastic crisis of chronic myeloid leukemia is well established, with three major changes [+8, +Ph, i(17q)] occurring alone or in combination in over 70% of the patients. The chromosome changes observed in different tissues may reveal the origin of the abnormal clones, as well as provide evidence for distinct or common evolution by different cell populations. The significance of the chromosome abnormalities and their relationship to blastic conversion are discussed. In general, chromosome evolution may be considered a rather reliable predictive or diagnostic parameter of blastic crisis but both the nature and the subsequent behavior of abnormal clones appear to be of critical value. As to the clinical/chromosome correlations, a few major points have emerged: the i(17q) aberration is mostly associated with signs of myeloid differentiation of blasts and a marked basophilia; it is mainly observed in the late stage of the disease, but overall median survival of patients with this marker is usually long; more atypical or complex changes usually are associated with a worse prognosis; patients with only a Ph in their blasts may have a longer survival, at least in some cytologic subgroups; and d) the loss of the Y chromosome seems to protect the cell against further clonal evolution. Finally, the relevance of the chromosome changes in the multistage process of blastic conversion is discussed, and the breakpoints of secondary changes recorded so far are reviewed and examined. It appears that certain chromosome regions are more often affected; these might contain genes of critical importance for the final malignant progression. Molecular biology may provide insight, in the future, on the nature and expression of involved genes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470135     DOI: 10.1016/0165-4608(87)90131-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Chromosome studies of solid tumours.

Authors:  N P Bown
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

2.  HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.

Authors:  Paolo Strati; Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Sergej Konoplev; Jeffrey L Jorgensen; Raja Luthra; Lynne Abruzzo; Elias Jabbour; Alfonso Quintas-Cardama; Gautam Borthakur; Stefan Faderl; Farhad Ravandi; Jorge Cortes
Journal:  Cancer       Date:  2013-10-22       Impact factor: 6.860

3.  Cytogenetics of chronic myelogenous leukemia (CML) correlated to the histopathology of bone marrow biopsies.

Authors:  M Werner; V Kaloutsi; T Buhr; S Delventhal; K F Vykoupil; A Georgii
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

4.  Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients.

Authors:  B Anger; F Carbonell; I Braunger; B Heinze; W Gutensohn; E Thiel; H Heimpel
Journal:  Blut       Date:  1988-09

5.  Case of CML lymphoid blast crisis presenting as bilateral breast masses.

Authors:  Aneesha Hossain; Kanika Gupta; Andrew Mener; Imad Tabbara
Journal:  BMJ Case Rep       Date:  2016-08-10

6.  Prognostic significance of isochromosome 17q in hematologic malignancies.

Authors:  Dorota Koczkodaj; Justyna Muzyka-Kasietczuk; Sylwia Chocholska; Monika Podhorecka
Journal:  Oncotarget       Date:  2021-03-30

7.  Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.

Authors:  K Mitani; S Ogawa; T Tanaka; H Miyoshi; M Kurokawa; H Mano; Y Yazaki; M Ohki; H Hirai
Journal:  EMBO J       Date:  1994-02-01       Impact factor: 11.598

8.  Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.

Authors:  T Skorski; M Nieborowska-Skorska; K Campbell; R V Iozzo; G Zon; Z Darzynkiewicz; B Calabretta
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.